Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland

• Authors: Artur Drzewiecki , Małgorzata Bulanda , Katarzyna Talaga , Anna Sodo , Paweł Adamski
• Languages of publication: EN

Abstracts

EN

In the study we tested drug sensitivity to 3 carbapenems (doripenem, imipenem and meropenem) of Gram-negative clinical isolates from Southern Poland.Material and methods. 89 strains were examined: 42 from Pseudomonas genus, 16 Acinetobacter baumannii strains and 31 Enterobacteriaceae strains. Etests were used according to the producers instructions, MIC values were interpreted using EUCAST criteria.Results. Highest in vitro activity against Pseudomonas spp. was shown for doripenem, then meropenem and the lowest for imipenem (MIC values were definitely lower for doripenem; differences were statistically significant); A. baumannii strains showed similar sensitivity to doripenem, meropenem and imipenem (differences non-significant); all Enterobacteriaceae strains showed sensitivity to the tested antimicrobials.Conclusions. As a conclusion-doripenem, which has high in vitro activity (almost the same as imipenem and meropenem) as well as beneficial pharmacologic properties, may be an alternative solution in the treatment of multiresistant Gram-negative bacteria, especially in patients in severe status who require restrictive antibiotic regimens.

Keywords

EN

doripenem   imipenem   meropenem   Enterobacteriaceae   Pseudomonas   Acinetobacter  

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2012
• Volume: 84
• Issue: 9
• Pages: 449-453

Dates

published

1 - 10 - 2012

online

23 - 10 - 2012

References

• 1. Nordmann P, PicazoJJ, Mutters R et al.: Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 2011; 66: 1070-78.[WoS]
• 2. Mendes RE , Rhomberg PR, Bell JM et al.: Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn Microbiol Infect Dis 2009; 63: 415-25.[WoS]
• 3. Kaniga K, Flamm R, Tong SY et al.: Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother 2010; 54: 2119-24.[WoS]
• 4. Livermore DM, Hope R, Brick G et al.: Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J AntimicrobChemother 2008; 62: ii55-ii63.[WoS]
• 5. Castanheira M, Jones RN , Livermore DM: Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009; 63: 426-33.[PubMed][WoS]
• 6. Fujimura T, Anan N, Sugimori G et al.: Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 2009; 34: 523-28.
• 7. EsterlyJS, Qi C, Malczynski M, Scheetz MH: Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and blaOXA gene status. Pharmacotherapy 2010; 30: 354-60.[WoS]
• 8. Marti S, Sánchez-Céspedes J, Alba V et al.: In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents 2009; 33: 181-82.[WoS]
• 9. Koomanachai P, Bulik CC , KutiJL et al.: Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010; 32: 766-79.[WoS]
• 10. Berthoin K, Le Duff CS , Marchand-Brynaert J et al.: Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010; 65: 1073-75.
• 11. Cirillo I, Vaccaro N, Turner K et al.: Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol 2009; 49: 798-806.
• 12. Katsube T, Yano Y, Wajima T et al.: Pharmacokinetic / pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem. J Pharm Sci 2010; 99: 2483-91.[PubMed]
• 13. Samtani MN , Flamm R, Kaniga K,Nandy P: Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010; 54: 2360-64.[PubMed]

Identifiers

DOI

10.2478/v10035-012-0076-2